Certara, Inc. has agreed to sell its Regulatory and Medical Writing business to Veristat, LLC for up to $135 million in cash and earn‑out consideration. The divestiture includes approximately 220 employees and is expected to close in the second quarter of 2026, subject to customary closing conditions.
The unit being sold generated $50 million in revenue and $17 million in adjusted EBITDA in 2025, underscoring its profitability and the scale of the transaction relative to Certara’s overall business. The deal structure provides $100 million in cash at closing, with up to $35 million in contingent earn‑out based on future performance and up to $15 million of the closing payment potentially held in escrow.
Certara’s CEO Jon Resnick said, "Certara's strategy is centered on expanding the scale, reach, and impact of our MIDD and Clinical Intelligence solutions." The sale allows the company to sharpen its focus on its core Model‑Informed Drug Development (MIDD) and Clinical Intelligence platforms, which are positioned for higher‑margin growth and are increasingly driven by AI integration.
Resnick added, "This transaction underlines our commitment to the acceleration of AI‑integrated modeling and simulation across the drug development lifecycle. Consistent with our strategy, we intend to deploy the proceeds to drive long‑term value for customers, patients, and shareholders." The proceeds are earmarked for accelerated investment in Certara’s integrated MIDD platform and to support the company’s broader AI‑enabled product roadmap.
For Veristat, the acquisition expands its regulatory‑writing portfolio and strengthens its service offering for biopharmaceutical clients. The transaction aligns with Veristat’s strategy to broaden its consulting and regulatory expertise across the drug development continuum.
The deal is reported as the largest divestiture of a regulatory‑writing unit in the life‑sciences services sector in 2026, reflecting a broader industry trend of companies divesting non‑core services to concentrate on scalable, technology‑driven solutions.
By divesting a high‑margin, services‑heavy unit, Certara positions itself to accelerate growth in its core software and analytics businesses, while Veristat gains a complementary capability that enhances its value proposition to clients. The transaction is expected to strengthen both companies’ competitive positions in their respective markets.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.